GLP-1 and GIP are both "incretin" hormones your gut releases after eating that help trigger insulin release, but they come from different cells and don't do identical jobs. GLP-1 also slows digestion and reduces appetite; GIP's effects on blood sugar are more glucose-dependent and its role in appetite is less clear-cut. Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) is a dual agonist that activates both the GIP and GLP-1 receptors. Retatrutide, still investigational and not FDA-approved, goes further as a triple agonist that also targets the glucagon receptor. More receptor targets is a different mechanism, not automatically a better outcome for every person.
Key takeaways
- GLP-1 and GIP are both incretin hormones released by the gut after eating, but from different cells with different downstream effects.
- Semaglutide is a single (GLP-1-only) agonist; tirzepatide is a dual GIP/GLP-1 agonist.
- Retatrutide is an investigational triple agonist (GLP-1 + GIP + glucagon receptors); it is not FDA-approved as of 2026.
- More receptor targets isn't automatically "better" for everyone; tolerability and individual response still vary.
What is GLP-1?
GLP-1, glucagon-like peptide-1, is a hormone released by L-cells lower in the small intestine and colon after you eat. It's part of a feedback loop called the "incretin effect," where the gut signals the pancreas that food has arrived. GLP-1's job is glucose-dependent: it stimulates the pancreas to release more insulin when blood sugar is elevated, and it suppresses glucagon (a hormone that raises blood sugar), so the two effects work together to blunt post-meal glucose spikes. GLP-1 also slows gastric emptying, so food leaves the stomach more gradually, and it acts on appetite-regulating regions of the brain to promote a feeling of fullness. That combination, steadier blood sugar plus reduced appetite, is the basis for both the diabetes and weight-management uses of GLP-1 receptor agonist drugs. Our GLP-1 basics guide covers this mechanism in more depth.
What is GIP?
GIP, glucose-dependent insulinotropic polypeptide, is the other major incretin hormone. It's released by K-cells higher up in the small intestine, and like GLP-1, it glucose-dependently stimulates insulin release. Where it diverges is its effect on glucagon: research describes GIP as a "bifunctional" regulator that can actually stimulate glucagon release when blood sugar is low or normal, helping guard against hypoglycemia, while having little added glucagon effect when blood sugar is high. That pattern appears to shift in people with type 2 diabetes. GIP's role in appetite and food intake is less settled than GLP-1's; some research has linked it to fat storage in certain contexts, and it's been described historically as having a smaller, less consistent effect on hunger. This is a genuinely more nuanced, still-evolving area of research than the appetite story for GLP-1, so treat GIP's appetite role as "actively studied" rather than fully mapped.
GLP-1 vs GIP, side by side
| GLP-1 | GIP | |
|---|---|---|
| Released by | L-cells, lower small intestine and colon | K-cells, upper small intestine |
| Insulin effect | Glucose-dependent stimulation | Glucose-dependent stimulation |
| Glucagon effect | Suppresses glucagon | Context-dependent: can raise glucagon when blood sugar is low, blunted effect when it's high |
| Gastric emptying | Slows it | Minimal established effect |
| Appetite | Reduces appetite via brain signaling | Less clear-cut; still an active research area |
| Drugs that target it alone | Semaglutide (Ozempic, Wegovy, Rybelsus) | No approved GIP-only drug |
The two hormones overlap on the core incretin job, glucose-dependent insulin release, but differ enough elsewhere that combining their receptors in one drug isn't redundant. That's the logic behind dual agonists.
What "agonist," "dual agonist" and "triple agonist" mean
A receptor agonist is simply a molecule that binds to a receptor and activates it, mimicking the body's own signal, similar to how a specific key turns a specific lock. A single agonist activates one receptor. A dual agonist is one molecule engineered to activate two different receptors at once. A triple agonist activates three. These terms describe the drug's mechanism, not its brand name or approved use, so it helps to keep the hormone (GLP-1, GIP) separate from the drug (semaglutide, tirzepatide) in your head.
Which drugs work on which hormones
- Semaglutide (Ozempic, Wegovy, Rybelsus) is a GLP-1 receptor agonist only, a single agonist built to closely mimic the body's own GLP-1.
- Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, one molecule that activates both incretin receptors. Structural pharmacology research describes it as "imbalanced," meaning it engages the GIP receptor somewhat more strongly than the GLP-1 receptor, which appears to be a deliberate design choice rather than an accident.
- Retatrutide is an investigational triple agonist that adds a third target, the glucagon receptor, on top of GLP-1 and GIP. It is not FDA-approved as of 2026 and remains in late-stage clinical trials, so its real-world safety and effectiveness picture is still being established. Its regulatory path has also been unusually unsettled, so treat any timeline for approval as provisional until it's officially confirmed.
See our semaglutide vs tirzepatide comparison for how the single-vs-dual mechanism plays out in trial results, dosing and side effects.
Does hitting more receptors mean a drug works better?
Trials so far do show a general trend: on average, dual agonists have outperformed single agonists in head-to-head weight and blood-sugar results, and early triple-agonist data has trended higher still. But "more receptors" isn't a free upgrade. GI side effects like nausea, diarrhea and vomiting tend to scale with a drug's overall potency across this entire class, not just with its target count, so a stronger multi-receptor effect can also mean a stronger tolerability trade-off for some people. Individual response also varies by genetics, dose, and how gradually the medication is titrated. In short: average trial results point one direction, but "best for the group" and "best for you" aren't the same question, and that question is one to work through with a clinician, not a headline statistic.
Frequently asked questions
What is the difference between GLP-1 and GIP?
Both are incretin hormones your gut releases after eating that help trigger insulin release. GLP-1 comes from L-cells lower in the intestine and also slows digestion and reduces appetite. GIP comes from K-cells higher up and has a more context-dependent effect on glucagon, with a less clear-cut role in appetite. Semaglutide-based drugs act only on the GLP-1 receptor; tirzepatide acts on both.
Is tirzepatide a GLP-1 or GIP drug?
Both. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist, a single molecule engineered to activate both incretin hormone receptors at once. That is different from semaglutide (Ozempic, Wegovy), which activates only the GLP-1 receptor.
What is a dual agonist?
An agonist is a molecule that binds to and activates a receptor, similar to how a key turns a lock. A dual agonist is one molecule built to activate two different receptors at once, for example tirzepatide activating both the GIP and GLP-1 receptors instead of just one.
How is retatrutide different?
Retatrutide is an investigational triple agonist studied in clinical trials, meaning it is designed to activate the GLP-1 receptor, the GIP receptor, and the glucagon receptor. As of 2026 it is not FDA-approved and remains in late-stage clinical testing, so any results should be considered early rather than confirmed real-world outcomes.
Does activating more receptors mean a drug works better?
Not automatically. Trials so far suggest dual and triple agonists can produce larger average results than single agonists, but GI side effects tend to scale with potency across the whole class, and individual response varies. More receptor targets is a different mechanism, not a guaranteed universal upgrade for every person.
Sources & further reading
- DailyMed: Ozempic (semaglutide) prescribing information
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist (PMC/NIH)
- The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health (MDPI, peer-reviewed review)
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity, Phase 2 Trial (New England Journal of Medicine)
- Glucagon-Like Peptide-1 Receptor Agonists overview, StatPearls (NCBI/NIH)